ABLYNX TO PRESENT AT THE 32nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE AND TO
PROVIDE AN UPDATE ON ITS TTP PROGRAMME
GHENT, Belgium, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:
ABLX] today announced that it will present at the 32^nd Annual J.P. Morgan
Healthcare Conference on Thursday 16 January 2014, at 2:00 p.m. Pacific Time
(5:00 p.m. Eastern Time).
Dr Edwin Moses, CEO of Ablynx, will give a corporate presentation that will
include an update on the Company's anti-vWF Nanobody, caplacizumab, to treat
acquired thrombotic thrombocytopenic purpura (TTP), a rare blood disorder.
Some improvement in recruitment has been seen since amending the clinical
protocol in September 2013, nevertheless, Ablynx has decided to stop
recruitment of the trial now to allow earlier analysis of the data for
potential proof-of-concept. Phase II data are now expected during the first
half of 2014 and if the results are promising, a Phase III study is
anticipated to commence in 2015.
The slides may be accessed via the Company's website, www.ablynx.com, under
the 'News and Events>upcoming events' section.
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 30 programmes in the pipeline and seven Nanobodies in
clinical development. Ablynx has on-going research collaborations and
significant partnerships with major pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The
Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
pdf version of the press release http://hugin.info/137912/R/1754015/591769.pdf
Press spacebar to pause and continue. Press esc to stop.